Low-potency oestrogen and risk of endometrial cancer: a case-control study.
about
Bioidentical hormones for menopausal hormone therapy: variation on a themePharmacology of estrogens and progestogens: influence of different routes of administrationGenetic variants in ER cofactor genes and endometrial cancer riskAdvances in the treatment of menopausal symptoms.Estrogen receptor alpha gene polymorphism and endometrial cancer risk--a case-control studyVulvovaginal atrophy.Schisandrae Fructus Reduces Symptoms of 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure in Mice.Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer.Off-label use of hormones as an antiaging strategy: a reviewHormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection.Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.Fruit and vegetable intake and risk of cancer in the Swedish women's lifestyle and health cohort.Dietary fat and breast cancer risk in the Swedish women's lifestyle and health cohort.Hormone replacement therapy in menopausal women: Past problems and future possibilities.Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer riskUltra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy.Gender and sex hormones in multiple sclerosis pathology and therapy.Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients.Endometrial cancer, types, prognosis, female hormones and antihormones.Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients.Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.Prospective study of coffee consumption and all-cause, cancer, and cardiovascular mortality in Swedish women.Hormone replacement therapy: reassessing the risks and benefits.Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy.Expression of estrogen and progesterone receptor genes in endometrium, myometrium and vagina of postmenopausal women treated with estriol.Current state of hormone replacement therapy: the case for using trimegestone.Alcoholism and risk for endometrial cancer.Estrogen receptor alpha gene polymorphisms and endometrial cancer risk.Effects of estriol on cell viability and 1,25-dihydroxyvitamin D3 receptor mRNA expression in cultured human osteoblast-like cells.Effects of combined estriol/pravastatin therapy on intima-media thickness of common carotid artery in hyperlipidemic postmenopausal women.The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women.
P2860
Q24643351-085B5CB4-9C29-4F6E-9726-7B98718F7198Q28268346-650465D1-F1C8-4836-8E13-4D4E8D8CC4E2Q28481918-F675ACDC-E439-421E-BFA8-16EB902D2C6DQ30448720-1D87F5D5-1C26-4791-956A-C01EE216A893Q30850668-09D1D92E-0F97-4983-B14A-BBBB9EEFD6A1Q33566744-21F1B593-51C5-464A-A908-A3F1B60F4EC5Q33726316-D25201F8-2808-4029-A253-2044EDEFA5D8Q33801778-1E694B78-1A94-400D-9D40-78C228EE2EE3Q33976165-2C5C7304-E184-44CF-80DD-7CD2CBB3B9AFQ34136769-83076599-3875-48A0-B3D7-D0CA3C5DBFA3Q34480625-BBC20B74-A762-4FF0-9340-2181B710F064Q34511458-51C1DFE7-32E5-4E6B-8045-4C61A26981B8Q36610673-C86E9E69-AAD8-4908-A550-AEA18FF7A39EQ36668526-8C1EA016-6337-41C9-8390-2816619BAF06Q36671453-9C9978E5-DACF-4999-B486-696F44A9B00FQ37206316-AF449520-7A94-4B04-AADB-E0AD4EFEF56DQ37209917-CBF18DD8-5661-42E7-9501-824744D19AD2Q37360543-9ADA9345-B978-4CD1-AED3-C659554CBDE5Q37438166-747DECAE-E7A8-4D04-9EF1-ADD566DAF498Q37855938-98A85AAB-89B4-40DC-8BD5-D4C86EEA8DC2Q37992713-6FA3AD0D-2DD8-46E9-A15E-EF93F142E220Q40210721-512A0521-5FEC-428F-AA97-F0BEC0527759Q41667887-D989452A-216F-4FD9-9787-92A565733B8CQ41686715-1AC9D846-AC3F-40BA-B103-3AB115F19481Q43084103-CB99AED2-5450-45F4-8E88-97F88EF0C1F2Q43263578-16998B0C-3DCB-4AEB-953D-EF4F1FC61491Q43267040-299ECF47-E876-4A55-9855-D182EC60CF2AQ43643752-7815500E-F1AA-4308-A651-56C2F1068600Q44630574-3E895B65-29DF-4F66-825A-009E098DCC57Q44781424-72059221-71F6-48D4-866C-186A4980B73FQ45150162-23685630-02C9-4F68-868B-E388AFA264E4Q45205625-FF1B4A6F-AB5E-4D7B-8025-D98CD16880EE
P2860
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
@ast
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
@en
type
label
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
@ast
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
@en
prefLabel
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
@ast
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
@en
P2093
P50
P1433
P1476
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
@en
P2093
P304
P356
10.1016/S0140-6736(98)10233-7
P407
P577
1999-05-01T00:00:00Z